Article

Early association of Vemurafenib to standard chemotherapy in multisystemic Langerhans cell histiocytosis in a newborn: take the chance for a better outcome?

2021-09-25

Abstract excerpt

LCH is an aberrant monoclonal proliferation of dendritic cells, ranging from a self-limiting local condition to a rapidly progressive multisystemic disease. Pathogenic cells expressed, in almost 70% of cases, an activation of the MAPK/ERK signaling pathway, in particular BRAF V600E mutation. We report on a newborn with multisystemic disease diagnosed in life-threatening medical conditions, who was successfully tre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 09d9a1f1-c65a-5d89-8683-314b715afc53
DOI: 10.22541/au.163255572.29603779/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early association of Vemurafenib to standard chemotherapy in multisystemic Langerhans cell histiocytosis in a newborn: take the chance for a better outcome?DOI 10.22541/au.163255572.29603779/v1Read

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.Semantic proximity Read

Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.Semantic proximity Read

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.Semantic proximity Read

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.Semantic proximity Read

Failure of salvage vemurafenib therapy for refractory multisystem Langerhans cell histiocytosis with BRAF-V600E mutationSemantic proximity Read

Vemurafenib provides a rapid and robust clinical response in paediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease based on ddPCR using cell-free circulating DNASemantic proximity Read

Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.Semantic proximity Read

Targeted Therapy with Vemurafenib in Brazilian Children with Refractory Langerhans Cell Histiocytosis: Two Case Reports and a Comprehensive ReviewSemantic proximity Read

[Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents].Semantic proximity Read

BRAF Mutated LCH: Diagnosis and Treatment Challenges - A High-Risk Case Presentation and Discussion.Semantic proximity Read

Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis.Semantic proximity Read